Highlights
- Radiopharm Theranostics will host an educational webinar on Pivalate on 14 June.
- The webinar will shed light on the company’s encouraging pre-IND meeting with the US FDA.
- The webinar will also cover the late-stage development plan for the technology and market opportunity.
Radiopharm Theranostics (ASX:RAD) is set to host an educational webinar on its Pivalate platform technology.
The webinar is aimed at delivering an overview on the company’s encouraging pre-Investigational New Drug (pre-IND) meeting with the US FDA. To know more about this development, read here.
Also, the webinar would spotlight the late-stage development plan for the technology and market opportunity.
Radiopharm CEO and Managing Director Riccardo Canevari would cover the updates during the webinar, which is due on 14 June 2023 at AEST 11 am.
Radiopharm Theranostics – A clinical-stage radiotherapeutics company
RAD has a pipeline of six platform technologies. The company is developing these technologies for diagnostic and therapeutic applications in areas of high unmet medical needs. The highly differentiated and distinct technologies cover peptides, small molecules, and monoclonal antibodies from some of the well-known universities and institutes.